Clincosm LogoSign in Get a demo

TNBC - Triple-Negative Breast Cancer

Showing 1 - 25 of 35
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

TNBC - Triple-Negative Breast Cancer Trial in Wuhan (Utidelone, Tirelizumab, Bevacizumab)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 5, 2023

TNBC - Triple-Negative Breast Cancer Trial in Brussels (Ga-PSMA PET/CT)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Ga-PSMA PET/CT
  • Brussels, Belgium
    Institut Jules Bordet
Sep 26, 2023

TNBC - Triple-Negative Breast Cancer Trial (Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Camrelizumab Plus Chemotherapy and Famitinib
  • Camrelizumab Plus Chemotherapy
  • (no location specified)
Aug 17, 2023

TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Alkaline Glucosodiene Molecules
  • (no location specified)
Jul 14, 2023

TNBC - Triple-Negative Breast Cancer Trial (A1:SG with SHR3680, A2:SG, B1:SG with SHR1210)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • A1:SG with SHR3680
  • +7 more
  • (no location specified)
Jun 23, 2023

Immunotherapy-related CRP Kinetics in Early and Metastatic

Recruiting
  • TNBC - Triple-Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 13, 2023

    TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • (no location specified)
    May 8, 2023

    TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

    Recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Nanjing, Jiangsu, China
      JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
    Apr 27, 2023

    Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)

    Recruiting
    • Triple Negative Breast Cancer
    • +14 more
    • LYL797
    • Scottsdale, Arizona
    • +10 more
    Jan 30, 2023

    Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head Neck Cancer Trial (CA9hu-1)

    Not yet recruiting
    • Clear Cell Renal Cell Carcinoma Metastatic
    • +4 more
    • (no location specified)
    Jan 13, 2023

    Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, NSCLC, Squamous or Non-squamous Trial in Denver,

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • +8 more
    • XmAb®808
    • Keytruda® (pembrolizumab)
    • Denver, Colorado
    • +2 more
    Jan 19, 2023

    HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)

    Recruiting
    • HER2-negative Breast Cancer
    • +3 more
    • Houston, Texas
      Houston Methodist Neal Cancer Center
    Jan 12, 2023

    Breast Cancer BRCA1 Carriers: a Pilot Study

    Withdrawn
    • BRCA1 Mutation
    • +2 more
    • Mifepristone 200 MG
    • Prophylactic mastectomy
    • Carmel, Indiana
    • +1 more
    Dec 13, 2022

    Non Small Cell Lung Cancer, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma Trial in United States (RTX-224)

    Terminated
    • Non Small Cell Lung Cancer
    • +4 more
    • Scottsdale, Arizona
    • +4 more
    Dec 7, 2022

    Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG

    Recruiting
    • Breast Neoplasms
    • +10 more
    • Standard Therapy
    • +32 more
    • Birmingham, Alabama
    • +35 more
    Nov 17, 2022

    TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial in Worldwide (Trilaciclib, Placebo, Gemcitabine)

    Active, not recruiting
    • TNBC - Triple-Negative Breast Cancer
    • Breast Cancer
    • Birmingham, Alabama
    • +111 more
    Oct 25, 2022

    Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)

    Completed
    Has Results
    • Triple Negative Breast Cancer
    • TNBC - Triple-Negative Breast Cancer
    • Birmingham, Alabama
    • +24 more
    Sep 19, 2022

    Immune Environment in Response to Therapy in Breast Cancer

    Recruiting
    • Breast Cancer
    • +3 more
    • Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.
    • Philadelphia, Pennsylvania
      Abramson Cancer Center
    Sep 15, 2022

    Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

    Recruiting
    • Breast Cancer
    • +2 more
      • Wuhan, Hubei, China
        TongjiHospital
      Sep 12, 2022

      Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

      Recruiting
      • Ovarian Cancer
      • +68 more
      • Phoenix, Arizona
      • +8 more
      Aug 18, 2022

      TNBC - Triple-Negative Breast Cancer, Breast Cancer Trial (Pembrolizumab, Radiation Therapy, Axatilimab)

      Not yet recruiting
      • TNBC - Triple-Negative Breast Cancer
      • Breast Cancer
      • (no location specified)
      Aug 4, 2022

      Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)

      Not yet recruiting
      • Breast Cancer
      • TNBC - Triple-Negative Breast Cancer
      • (no location specified)
      Aug 5, 2022

      TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in United States (Sterotactic Body

      Active, not recruiting
      • TNBC - Triple-Negative Breast Cancer
      • +6 more
      • Sterotactic Body Radiotherapy/SBRT
      • Standard of care
      • Basking Ridge, New Jersey
      • +8 more
      Jul 26, 2022

      Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant Trial in Bethesda, Nashville (TC-510, Fludarabine,

      Recruiting
      • Mesothelioma
      • +14 more
      • TC-510
      • +2 more
      • Nashville, Tennessee
        Sarah Cannon Research Institute
      Jul 14, 2022

      Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in United States (TH1902)

      Recruiting
      • Solid Tumor
      • +8 more
      • Los Angeles, California
      • +5 more
      Jun 27, 2022